Administration of a therapeutic amount of genistein to mitigate erectile dysfunction resulting from radiation therapy for prostate cancer only throughout a defined administration period commencing shortly before and concluding after radiation therapy

US9623004B2 · kind B2 · utility

Inventors

• Michael D. Kaytor · Maplewood, US
• John L. Zenk · Eden Prairie, US
• Geoffrey E. Schroeder · Woodbury, US
• Zeljko Vujaskovic · Baltimore, US
• Isabel Lauren Jackson · Baltimore, US

Key dates

• Filing date: Jul 30, 2014
• Grant date: Apr 18, 2017
• Expiry date: Jul 30, 2034

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P15/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A method for mitigating erectile dysfunction as an adverse side effect of radiation therapy for prostate cancer, comprising administration of a therapeutic dosage of genistein to a patient diagnosed with prostate cancer throughout only a primary administration period that commences a defined period of up to two weeks prior to commencement of radiation therapy for prostate cancer and extends beyond conclusion of the radiation therapy.